AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ASND · NASDAQ · Biotechnology

Ascendis Pharma (ADR) (ASND)

Builds and commercializes rare-endocrinology medicines through the TransCon prodrug platform.

$227.71

vs last close−9.86 (−4.15%)

In millions of USD, except per-share figures · converted from EUR at the latest rate

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	55	157	109	41	66	198	115	180	243	279	286	393
Cost of revenue	8	22	9	13	13	16	20	36	25	31	25	37
Gross profit	46	135	101	28	53	182	95	144	218	248	261	356
	200	176	157	180	163	182	214	205	205	237	232	284
Research & development	127	104	81	95	84	90	99	82	76	85	66	85
	71	73	76	85	78	90	109	120	127	152	167	199
Selling & marketing	0	0	0	2	0	0	0	0	0	0	0	0
General & administrative	71	0	0	82	78	90	109	120	127	0	0	0
Other expenses	1	0	0	0	2	2	6	2	2	0	0	0
Operating income	−153	−42	−56	−152	−110	0	−119	−60	13	11	29	72
	−31	−51	−90	27	−2	−43	12	20	−78	−41	−85	194
Interest income	5	0	4	56	32	−76	33	63	4	27	5	23
Interest expense	28	78	88	22	29	−65	51	38	22	70	78	16
Other non-operating income	3	41	3	−50	−27	49	−63	−58	78	−29	7	0
Income before tax	−184	−92	−146	−124	−112	−43	−107	−40	−65	−30	−56	267
Income tax expense	1	7	3	0	1	1	1	4	4	8	−785	27
Net income from continuing operations	−185	−99	−149	−125	−113	−44	−108	−44	−70	−38	729	240
Net income	−185	−99	−149	−125	−113	−44	−108	−44	−70	−38	729	240
EPS, basic	−$3.28	−$1.74	−$2.62	−$2.18	−$1.93	−$0.73	−$1.80	−$0.73	−$1.14	−$0.62	$11.82	$3.73
EPS, diluted	−$3.28	−$1.74	−$2.62	−$2.18	−$1.93	−$0.73	−$1.80	−$0.93	−$1.14	−$0.62	$11.29	$3.51
Weighted average shares, basic	56	57	57	57	59	60	60	60	61	61	62	64
Weighted average shares, diluted	56	57	57	57	59	60	60	64	61	61	65	68
EBITDA	−151	−77	−53	−100	−81	−43	−50	3	−61	45	27	78
Depreciation & amortization	6	6	5	2	2	5	5	5	5	5	5	5
EBIT	−156	−83	−59	−102	−83	−48	−56	−2	−65	40	22	72